Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1218)	5/25/1999 12:31:00 AM
From: VeloSpeed	Read Replies (1) \| Respond to of 1826

What's next for these guys now that ASCO has come and gone without some big run-up? Any dates to mark on the calender? no time to research anything lately... -VeloSpeed

To: Jim Oravetz who wrote (1218)	7/16/1999 12:52:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 1826

DJ MGI Pharma, Pharmacia&Upjohn To Co-Mkt Arthritis Drug MINNEAPOLIS (Dow Jones)--MGI Pharma Inc. (MOGN) and Pharmacia & Upjohn Inc. (PNU) agreed to co-promote Azulfidine EN-tabs in the U.S. for patients with rheumatoid arthritis who haven't responded well to other treatment. Terms weren't disclosed. In a press release Thursday, MGI Pharma said it expects "nominal" sales from Azulfidine EN-tabs in 1999, and modest, but more "meaningful" sales in 2000 after the two companies launch the joint marketing campaign in September. Jim